Nationwide study on the prevalence of rheumatoid factor and anticitrullinated peptide positivity and their contribution to rheumatoid arthritis diagnosis.
Autoantibody
anticitrullinated peptide
nationwide
rheumatoid arthritis
rheumatoid factor
Journal
Turkish journal of medical sciences
ISSN: 1303-6165
Titre abrégé: Turk J Med Sci
Pays: Turkey
ID NLM: 9441758
Informations de publication
Date de publication:
2024
2024
Historique:
received:
04
01
2021
revised:
18
10
2024
accepted:
07
10
2024
medline:
30
10
2024
pubmed:
30
10
2024
entrez:
30
10
2024
Statut:
epublish
Résumé
Rheumatoid factor (RF) and anticitrullinated peptide (anti-CCP) are specific for rheumatoid arthritis (RA) diagnosis. However, they could be positive in other diseases and even in healthy populations. The aim was to investigate the prevalence of positive RF and anti-CCP antibodies in persons admitted to hospital for any reason and on a national scale. The National Electronic Health Database, which contains the clinical records of over 80 million people, was used to design this multicenter, retrospective cohort study. The subjects included in the study were divided into age groups according to 10-year periods. RA cases were identified using ICD-10 codes that included M05, M06, M08, and their subgroups. RF and anti-CCP positivity were evaluated in terms of their contribution to the risk of being diagnosed with RA, with the change according to age and sex. During the 1.1.2018-31.12.2021 period, 13,918,072 RF tests were performed in 11,849,440 people, whereas 1,183,607 anti-CCP tests were performed in 1,020,967 people. Moreover, 797,089 people had both tests performed at least once. The RF positivity rate in patients who only requested RF tests was 14.72% and it was 35.04% for anti-CCP positivity in those who only requested anti-CCP tests. The rate of concomitant RF and anti-CCP positivity was 22.56%. An RA diagnosis was made in 27.8% of RF-positive people, 39.73% of anti-CCP-positive people, and 56.6% of co-RF and anti-CCP-positive people. RF positivity and concomitant RF and anti-CCP positivity increased with age and were more common in females. RF and anti-CCP positivity may be seen in a healthy population with female predominance. As age increases, the risk of RF positivity rises, but anti-CCP positivity does not change. Concomitant RF and anti-CCP positivity shows the highest risk of RA development with respect to either antibody positivity alone.
Sections du résumé
Background/aim
UNASSIGNED
Rheumatoid factor (RF) and anticitrullinated peptide (anti-CCP) are specific for rheumatoid arthritis (RA) diagnosis. However, they could be positive in other diseases and even in healthy populations. The aim was to investigate the prevalence of positive RF and anti-CCP antibodies in persons admitted to hospital for any reason and on a national scale.
Materials and methods
UNASSIGNED
The National Electronic Health Database, which contains the clinical records of over 80 million people, was used to design this multicenter, retrospective cohort study. The subjects included in the study were divided into age groups according to 10-year periods. RA cases were identified using ICD-10 codes that included M05, M06, M08, and their subgroups. RF and anti-CCP positivity were evaluated in terms of their contribution to the risk of being diagnosed with RA, with the change according to age and sex.
Results
UNASSIGNED
During the 1.1.2018-31.12.2021 period, 13,918,072 RF tests were performed in 11,849,440 people, whereas 1,183,607 anti-CCP tests were performed in 1,020,967 people. Moreover, 797,089 people had both tests performed at least once. The RF positivity rate in patients who only requested RF tests was 14.72% and it was 35.04% for anti-CCP positivity in those who only requested anti-CCP tests. The rate of concomitant RF and anti-CCP positivity was 22.56%. An RA diagnosis was made in 27.8% of RF-positive people, 39.73% of anti-CCP-positive people, and 56.6% of co-RF and anti-CCP-positive people. RF positivity and concomitant RF and anti-CCP positivity increased with age and were more common in females.
Conclusion
UNASSIGNED
RF and anti-CCP positivity may be seen in a healthy population with female predominance. As age increases, the risk of RF positivity rises, but anti-CCP positivity does not change. Concomitant RF and anti-CCP positivity shows the highest risk of RA development with respect to either antibody positivity alone.
Identifiants
pubmed: 39473762
doi: 10.55730/1300-0144.5872
pii: tjmed-54-05-949
pmc: PMC11518367
doi:
Substances chimiques
Rheumatoid Factor
9009-79-4
Anti-Citrullinated Protein Antibodies
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
949-955Informations de copyright
© TÜBİTAK.
Déclaration de conflit d'intérêts
Conflict of interest: The authors declare that they have no conflict of interest.
Références
Arthritis Res. 2002;4 Suppl 3:S265-72
pubmed: 12110146
Clin Rheumatol. 2010 Dec;29(12):1345-51
pubmed: 20686805
Ann Rheum Dis. 2006 Jul;65(7):845-51
pubmed: 16606649
Ann Rheum Dis. 2008 Jun;67(6):860-6
pubmed: 17644543
Am J Med. 1991 Nov;91(5):528-34
pubmed: 1951415
Arthritis Rheum. 2010 Sep;62(9):2569-81
pubmed: 20872595
Arch Rheumatol. 2017 Oct 13;33(2):128-136
pubmed: 30207568
Best Pract Res Clin Rheumatol. 2018 Apr;32(2):174-187
pubmed: 30527425
Ann Rheum Dis. 2017 Jul;76(7):1184-1190
pubmed: 28043998
Rheumatol Int. 2013 Apr;33(4):939-42
pubmed: 22829412
Eur J Immunol. 1997 Mar;27(3):735-41
pubmed: 9079816
Int J Rheum Dis. 2010 Oct;13(4):380-4
pubmed: 21199474
Arthritis Res Ther. 2020 Oct 15;22(1):242
pubmed: 33059732
Rheumatology (Oxford). 2020 Dec 1;59(12):3759-3766
pubmed: 32413107
Zhonghua Nei Ke Za Zhi. 2011 Feb;50(2):99-101
pubmed: 21418826
Ann Rheum Dis. 2005 Feb;64(2):330-2
pubmed: 15647444
Clin Rheumatol. 2013 Jul;32(7):1089-93
pubmed: 23515604
Rheumatology (Oxford). 2010 Aug;49(8):1590-3
pubmed: 20457731
Dis Markers. 2013;35(6):727-34
pubmed: 24324289
Clin Rheumatol. 2005 Jun;24(3):212-4
pubmed: 15940553
Ann Intern Med. 2007 Jun 5;146(11):797-808
pubmed: 17548411
Clin Exp Rheumatol. 2004 Jul-Aug;22(4):416-20
pubmed: 15301237
Rheumatol Int. 2012 Apr;32(4):895-908
pubmed: 21229358
Arthritis Care Res (Hoboken). 2014 Dec;66(12):1818-27
pubmed: 24942650